Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals’s JZP-898?
JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Renal Cell Carcinoma;Metastatic Transitional (Urothelial) Tract Cancer.
JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Renal Cell Carcinoma;Metastatic Transitional (Urothelial) Tract Cancer.
What's Your Reaction?
